Perspective Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CATX research report →
About the company
Perspective Therapeutics, Inc. , including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally.
- CEO
- Johan Spoor
- IPO
- 2005
- Employees
- 138
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $280.42M
- P/E
- -0.14
- P/S
- 453.75
- P/B
- 0.01
- EV/EBITDA
- -2.08
- Div Yield
- 0.00%
- Gross Margin
- -489.81%
- Op Margin
- -19419.58%
- Net Margin
- -17982.69%
- ROE
- -41.84%
- ROIC
- -31.33%
- Revenue
- $0 · -100.00%
- Net Income
- $-103,121,000 · -30.07%
- EPS
- $-1.40 · -13.82%
- Op Income
- $-113,564,000
- FCF YoY
- -30.98%
- 52W High
- $6.16
- 52W Low
- $1.96
- 50D MA
- $3.60
- 200D MA
- $3.59
- Beta
- 1.73
- Avg Volume
- 1.63M
Get TickerSpark's AI analysis on CATX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 26 | Martinez Maria E | other | 50,000 |
| Mar 2, 26 | Morich Frank | other | 50,000 |
| Mar 2, 26 | Williamson Robert F III | other | 50,000 |
| Mar 2, 26 | HENSON HEIDI | other | 50,000 |
| Mar 2, 26 | Woods Lori A | other | 50,000 |
| Mar 2, 26 | Spoor Johan M. | other | 735,000 |
| Mar 2, 26 | Hunt Jonathan Robert | other | 90,000 |
| Mar 2, 26 | Puhlmann Markus | other | 150,000 |
| Nov 13, 25 | Hunt Jonathan Robert | buy | 11,000 |
| Nov 12, 25 | Williamson Robert F III | buy | 9,498 |
Our CATX coverage
Recent articles, reports, and earnings notes.
No research on CATX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CATX report →Similar companies
Peers in the same neighborhood.